Seattle Genetics, Millennium complete patient enrolment in Phase III trial of Adcetris
The randomised, double-blind trial will compare progression-free survival in 329 post-ASCT patients receiving Adcetris to those receiving placebo. Patients receive Adcetris every three weeks for up to one
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.